KR102461210B1 - Uti 융합 단백질 - Google Patents

Uti 융합 단백질 Download PDF

Info

Publication number
KR102461210B1
KR102461210B1 KR1020167026429A KR20167026429A KR102461210B1 KR 102461210 B1 KR102461210 B1 KR 102461210B1 KR 1020167026429 A KR1020167026429 A KR 1020167026429A KR 20167026429 A KR20167026429 A KR 20167026429A KR 102461210 B1 KR102461210 B1 KR 102461210B1
Authority
KR
South Korea
Prior art keywords
gly
ser
val
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167026429A
Other languages
English (en)
Korean (ko)
Other versions
KR20160141718A (ko
Inventor
애런 챔벌린
퀴앙 리우
마티아스 슈미트
Original Assignee
다케다 게엠베하
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 게엠베하, 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 게엠베하
Priority to KR1020227037377A priority Critical patent/KR102722304B1/ko
Publication of KR20160141718A publication Critical patent/KR20160141718A/ko
Application granted granted Critical
Publication of KR102461210B1 publication Critical patent/KR102461210B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
KR1020167026429A 2014-02-24 2015-02-23 Uti 융합 단백질 Active KR102461210B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227037377A KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037377A Division KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Publications (2)

Publication Number Publication Date
KR20160141718A KR20160141718A (ko) 2016-12-09
KR102461210B1 true KR102461210B1 (ko) 2022-10-31

Family

ID=52629709

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167026429A Active KR102461210B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020227037377A Active KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020247035230A Pending KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227037377A Active KR102722304B1 (ko) 2014-02-24 2015-02-23 Uti 융합 단백질
KR1020247035230A Pending KR20240155987A (ko) 2014-02-24 2015-02-23 Uti 융합 단백질

Country Status (38)

Country Link
US (4) US9856310B2 (enExample)
EP (2) EP3443978A1 (enExample)
JP (4) JP6574431B2 (enExample)
KR (3) KR102461210B1 (enExample)
CN (2) CN110092837B (enExample)
AR (1) AR101597A1 (enExample)
AU (4) AU2015218704B2 (enExample)
BR (1) BR112016019390B1 (enExample)
CA (2) CA3178241A1 (enExample)
CL (1) CL2016002136A1 (enExample)
CR (1) CR20160444A (enExample)
CY (1) CY1120997T1 (enExample)
DK (1) DK3110434T3 (enExample)
DO (1) DOP2016000202A (enExample)
EA (2) EA202091567A1 (enExample)
EC (1) ECSP16076535A (enExample)
ES (1) ES2700149T3 (enExample)
GE (1) GEP20196970B (enExample)
HR (1) HRP20182029T1 (enExample)
IL (1) IL247321B (enExample)
JO (1) JO3729B1 (enExample)
LT (1) LT3110434T (enExample)
MA (1) MA39347B2 (enExample)
MX (4) MX2016010950A (enExample)
MY (1) MY178774A (enExample)
NZ (3) NZ760789A (enExample)
PE (1) PE20170257A1 (enExample)
PH (1) PH12016501629B1 (enExample)
PL (1) PL3110434T3 (enExample)
PT (1) PT3110434T (enExample)
RS (1) RS58285B1 (enExample)
SG (2) SG11201606691QA (enExample)
SI (1) SI3110434T1 (enExample)
SM (1) SMT201800674T1 (enExample)
TW (1) TWI694084B (enExample)
UA (1) UA118866C2 (enExample)
WO (1) WO2015127391A1 (enExample)
ZA (1) ZA201606327B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3110434T (pt) * 2014-02-24 2018-12-19 Takeda Pharmaceuticals Co Proteínas da fusão de uti
KR20200033840A (ko) * 2017-06-07 2020-03-30 스파크 테라퓨틱스, 인코포레이티드 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044554A (zh) * 2012-05-14 2013-04-17 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE59007737D1 (de) * 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
AU641568B2 (en) 1990-11-13 1993-09-23 Mochida Pharmaceutical Co., Ltd. Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3469584B2 (ja) 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
WO2007011363A2 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
JP5632126B2 (ja) 2005-12-29 2014-11-26 ダイアックス コーポレーション プロテアーゼ阻害
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
MX2011011815A (es) * 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
LT2536745T (lt) * 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
KR20250037576A (ko) * 2011-04-29 2025-03-17 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
EP2842969B1 (en) * 2012-04-23 2018-03-14 NRL Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
PT3110434T (pt) * 2014-02-24 2018-12-19 Takeda Pharmaceuticals Co Proteínas da fusão de uti

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044554A (zh) * 2012-05-14 2013-04-17 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用

Also Published As

Publication number Publication date
CL2016002136A1 (es) 2017-08-11
KR20220151005A (ko) 2022-11-11
US9856310B2 (en) 2018-01-02
MA39347A1 (fr) 2018-06-29
NZ724196A (en) 2022-01-28
MA39347B2 (fr) 2020-05-29
PL3110434T3 (pl) 2019-01-31
CN106232135B (zh) 2019-12-10
JO3729B1 (ar) 2021-01-31
KR20240155987A (ko) 2024-10-29
MY178774A (en) 2020-10-20
KR20160141718A (ko) 2016-12-09
AU2023200875A1 (en) 2023-04-27
EA201691702A1 (ru) 2017-01-30
CN110092837B (zh) 2024-01-02
EA037256B1 (ru) 2021-02-26
US10351618B2 (en) 2019-07-16
WO2015127391A1 (en) 2015-08-27
CA3178241A1 (en) 2015-08-27
JP2017512058A (ja) 2017-05-18
LT3110434T (lt) 2018-12-27
AU2021225156A1 (en) 2021-09-30
CY1120997T1 (el) 2019-12-11
JP2023123763A (ja) 2023-09-05
SG10201708400QA (en) 2017-11-29
AU2019204448B2 (en) 2021-06-10
US20160362475A1 (en) 2016-12-15
AU2021225156B2 (en) 2022-11-24
DK3110434T3 (en) 2019-01-14
KR102722304B1 (ko) 2024-10-28
IL247321A0 (en) 2016-09-29
GEP20196970B (en) 2019-04-25
NZ760789A (en) 2023-03-31
PE20170257A1 (es) 2017-03-30
EP3443978A1 (en) 2019-02-20
TW201630931A (zh) 2016-09-01
PH12016501629A1 (en) 2017-02-06
PH12016501629B1 (en) 2023-10-20
CR20160444A (es) 2017-04-21
MX2019013124A (es) 2020-08-31
UA118866C2 (uk) 2019-03-25
EP3110434B1 (en) 2018-09-19
JP6574431B2 (ja) 2019-09-11
HRP20182029T1 (hr) 2019-02-08
SG11201606691QA (en) 2016-09-29
PT3110434T (pt) 2018-12-19
IL247321B (en) 2020-06-30
JP2022002513A (ja) 2022-01-11
US20200040062A1 (en) 2020-02-06
MX384070B (es) 2025-03-14
BR112016019390A2 (pt) 2017-10-24
SI3110434T1 (sl) 2019-02-28
US20220127334A1 (en) 2022-04-28
AR101597A1 (es) 2016-12-28
JP6938565B2 (ja) 2021-09-22
MX2024000004A (es) 2024-02-20
AU2015218704A1 (en) 2016-09-22
ES2700149T3 (es) 2019-02-14
AU2015218704B2 (en) 2019-05-02
RS58285B1 (sr) 2019-03-29
CA2939639C (en) 2023-01-24
EP3110434A1 (en) 2017-01-04
CN106232135A (zh) 2016-12-14
EA202091567A1 (ru) 2021-07-30
JP2019187427A (ja) 2019-10-31
US20180072795A1 (en) 2018-03-15
CA2939639A1 (en) 2015-08-27
AU2019204448A1 (en) 2019-07-11
NZ760008A (en) 2023-03-31
MX2016010950A (es) 2017-04-25
BR112016019390B1 (pt) 2023-11-14
CN110092837A (zh) 2019-08-06
ZA201606327B (en) 2019-01-30
TWI694084B (zh) 2020-05-21
SMT201800674T1 (it) 2019-01-11
DOP2016000202A (es) 2016-12-15
ECSP16076535A (es) 2017-08-31

Similar Documents

Publication Publication Date Title
KR102461210B1 (ko) Uti 융합 단백질
KR20150041628A (ko) 인터루킨-2 융합 단백질 및 그의 용도
JP2016522795A (ja) ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
HK40004244A (en) Uti fusion proteins
HK1232783A1 (en) Uti fusion proteins
HK1232783B (en) Uti fusion proteins
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos, composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000